manufacturers of glp-1 drugs Market Overview: Agonists and the Obesity Market | Blog GLP-1s in the “Barbecue Belt
Description
160,161 For example, HM15211, a triple agonist developed by Hanmi Pharmaceutical in South Korea that activates GLP-1R, GIPR and GCGR has entered early clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH)
Tanokashira D, Fukuokaya W, Taguchi A
Human evidence - Phase 2 MASLD substudy (Sanyal et al., Nature Medicine 2024) Adults with MASLD and at least 10% liver fat
The evaluating clinician determines which option is appropriate based on your individual health factors
Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors
doi:10.1248/bpb.31.925
